Model of huntington's disease induced with 3-nitropropionic acid;Modelo de enfermedad de Huntington inducido con ácido 3-nitropropiónico

Revista de Neurologia

Volumn 48, Issue 8, 2009, Pages 430-434

  Tunez I ^a   Santamaria A ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

3 nitropropionic acid; Energetic metabolism; Huntington's disease; Oxidative stress; Succinate dehydrogenase

Indexed keywords

3 NITROPROPIONIC ACID; HUNTINGTIN; SUCCINATE DEHYDROGENASE;

ANIMAL MODEL; DISEASE ASSOCIATION; DISEASE MODEL; ENZYME ACTIVITY; HUNTINGTON CHOREA; MOLECULAR MODEL; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; REVIEW;

EID: 65449129628     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4808.2008678     Document Type: Review

References (63)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
2. Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, et al. Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med 2008; 8: 221-34.
3. Walker FO. Huntington's disease. Lancet 2007; 369: 218.
4. García-Ramos J, del Val-Fernández J, Catalán-Alonso MJ, Barcía-Albacar JA, Matías-Guiu J. Modelos experimentales de la enfermedad de Huntington. Rev Neurol 2007; 45: 437-41.
5. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. ILAR J 2007; 48: 356-73.
6. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-84.
7. Kremer HP, Ross RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 1991; 132: 101-4.
8. Ferrante RJ, Kowall NW, Richardson EP Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease a combined study using the section-Golgi method and calbindin D28K immunocytochemistry. J Neurosci 1991; 11: 3877-87.
9. Eskenazi BR, Wilson-Rich NS, Starks PT. A Darwinian approach to Huntington's disease: subtle health benefits of a neurological disorder. Med Hypotheses 2007; 69: 1183-9.
10. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3.
11. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 27: 2803-20.
12. Ouary S, Bizat N, Altairac S, Mnetrat H, Mittoux V, Conde F, et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 2000; 97: 521-30.
13. Borlongan CV, Koutouzis K, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model. Brain Res Brain Res Protoc 1997; 1: 253-7.
14. Brouillet E, Jacquard C, Bizat N, Blum D. 3-nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005; 95: 1521-40.
15. Túnez I, Montilla P, Muñoz MC, Feijóo M, Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 2004; 37: 252-6.
16. Túnez I, Feijóo M, Collado JA, Peña J, Muñoz MC, Jimena I, et al. Effect of testosterone on oxidative stress and cell damage induced by 3- nitropropionic acid in striatum of ovariectomized rats. Life Sci 2007; 80: 1221-7.
17. Túnez I, Collado JA, Medina FJ, Peña J, Muñoz MC, Jimena I, et al. 17 beta-estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats. Neurochem Int 2006; 48: 367-73.
18. Túnez I, Muñoz MC, Montilla P. Treatment with dehydroepiandrosterone prevents oxidative stress induce by 3-nitropropionic acid in synaptosomes. Pharmacology 2005; 74: 113-8.
19. Borlongan CV, Koutouzis TK, Sanberg PR. 3-nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 1997; 21: 289-93.
20. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997; 79: 45-56.
21. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181-92.
22. Brouillet E, Guyot MC, Mittoux V, Altairac S, Conde F, Palfi S, et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 1998; 70: 794-805.
23. Borlongan CV, Koutouzis TK, Freeman TB, Cahill DW, Sanberg PR. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res 1995; 697: 254-7.
24. Borlongan CV, Koutouzis TK, Cahill DW, Freeman TB, Sanberg PR. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res Bull 1995; 36: 549-56.
25. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willing A, Kowall NW, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995; 92: 7105-9.
26. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 1996; 16:3019-25.
27. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996; 39: 385-9.
28. Tabrizzi SJ, Cleeter MW, Xucreb J, Taanman JW, Cooper JM, Schapira AH. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999; 45: 25-32.
29. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976; 263: 244-6.
30. Alston TA, Mela L, Bright HJ. 3-nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci U S A 1977; 74: 3767-71.
31. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin MF. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-71.
32. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278: 37948-56.
33. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochem Int 2003; 43: 89-99.
34. Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN, et al. Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol Dis 2004; 15: 152-9.
35. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205-12.
36. Beal MF. Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 1994; 7: 542-7.
37. Nasr P, Carbery T, Geddes JW. N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem Res 2009; 34: 490-8.
38. Ryu JK, Nagai A, Kim J, Lee MC, McLarnon JG, Kim SU. Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid in vitro and in vivo studies. Neurol Dis 2003; 12: 121-32.
39. Ohgoh M, Shimizu H, Ogura H, Nishizawa Y. Astroglial trophic support and neuronal cell death: influence of cellular energy level on type of cell death induced by mitochondrial toxin in cultured rat cortical neurons. J Neurochem 2000; 75: 925-33.
40. 2+ exchanger. Exp Neurol 1997; 145: 38-45.
41. Nishino H, Hida H, Kumazaki M, Shimano Y, Nakajima K, Shimizu H, et al. The striatum is the most vulnerable region in the brain to mitochondrial energy compromise a hypothesis to explain its specific vulnerability. J Neurotrauma 2000; 17: 251-60.
42. Yang L, Calingasan NY, Chen J, Ley JJ, Becker DA, Beal MF. A novel azulenyl nitrone antioxidant protects agains MPTP and 3-nitropropionic acid neurotoxicities. Exp Neurol 2005; 191: 86-93.
43. Palfi S, Leventhal L, Goetz CG, Hantraye T, Roitberg BZ, Sramek J, et al. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 2000; 15: 524-30.
44. Herrera-Mundo MN, Silva-Adaya D, Maldonado PD, Galván-Arzate S, Andrés-Martínez L, Pérez de la Cruz V, et al. S-allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction. Neurosci Res 2006; 56: 39-44.
45. Pérez de la Cruz V, Konigsberg M, Pedraza-Chaverri J, Herrera-Mundo N, Díaz-Muñoz M, Morán J, et al. Cytoplasmic calcium mediates oxidative damage in an excitotoxic/energetic deficit synergic model in rats. Eur J Neurosci 2008; 27: 1075-85.
46. Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, et al. ¿Es la vieja minociclina un nuevo fármaco neuroprotector? Rev Neurol 2008; 47:31-8.
47. Pang Z, Geddes JW. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J Neurosci 1997; 17: 3064-73.
48. Villarán RF, Tomás-Camardiel M, De Pablos RM, Santiago M, Herrera AJ, Navarro A, et al. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 2008; 29: 244-58.
49. Maragos WF, Young KL, Altman CS, Pocernich CB, Drake J, Butterfield DA, et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res 2004; 29: 741-6.
50. Canals JM, Checa N, Marco S, Akerud P, Michels A, Perez-Navarro E, et al. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J Neurosci 2001; 21: 117-24.
51. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38.
52. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81: 294-330.
53. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-60.
54. Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science 2002; 295: 1729-34.
55. Ernfors P, Bramham CR. The coupling of a trkB tyrosine residue to LTP. Trends Neurosci 2003; 26: 171-3.
56. Hock C, Heese K, Hulette C, Rosengerg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain- derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-51.
57. Gao X, Talalay P. Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proc Natl Acad Sci U S A 2004; 101: 10446-51.
58. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 2005; 102:244-9.
59. Almeida S, Brett AC, Góis IN, Oliveira CR, Rego C. Caspase-dependent and -independent cell death induced by 3-nitropropionic acid in rat cortical neurons. J Biol Chem 2006; 98: 93-101.
60. Minn Y, Cho KJ, Kim HW, Kim HJ, Suk SH, Lee BI, et al. Induction of apoptosis signal-regulating kinase 1 and oxidative stress mediate age- dependent vulnerability to 3-nitropropionic acid in the mouse striatum. Neurosci Lett 2008; 430: 142-6.
61. Pelegri C, Durán-Vilaregut J, Del Valle J, Crespo-Biel N, Pallàs M, Camins A, et al. Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int J Dev Neurosci 2008; 26: 665-71.
62. Park DS, Obeidat A, Giovanni A, Greene LA. Cell cycle regulators in neuronal death evoked by excitotoxic stress: implications for neurode- generation and its treatment. Neurobiol Aging 2000; 21: 771-81.
63. Napolitano M, Zei D, Centonze D, Palermo R, Benerdi G, Vacca A, et al. NF-KB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease. Neurosci Lett 2008; 343:241-6.